Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 60Unknown 9Terminated 8Withdrawn 2Recruiting 1No longer available 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Myelodysplastic Syndromes 10Burkitt Lymphoma 9Lymphoma, Mantle-Cell 6Leukemia, Biphenotypic, Acute 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Leukemia 4Recurrence 3Myeloproliferative Disorders 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myelomonocytic, Chronic 3Down Syndrome 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Monocytic, Acute 2Blast Crisis 2Vasculitis, Central Nervous System 1Stiff-Person Syndrome 1Rasmussen subacute encephalitis 1Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1Plasmablastic Lymphoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pathologic Complete Response 1Opsoclonus-Myoclonus Syndrome 1Neuromyelitis Optica 1Neoplasms 1

Interventions

vedolizumab 1Injections 1Genetic Testing 1Gene Expression Profiling 1Gemtuzumab 1Decitabine 1Daunorubicin 1Cytarabine 1Calcineurin Inhibitors 1CPX-351 1Azacitidine 1Amplified Fragment Length Polymorphism Analysis 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Myelomonocytic, Acute × Cytarabine × Clear all
NCT01627041 2026-04-27

Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
178 enrolled
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡